arrow
P

Patricia Troncoso

The University of Texas MD Anderson Cancer Center
H指数:94
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Talazoparib联合恩扎卢胺治疗高负荷转移性激素未治前列腺癌:一项随机Ⅱ期试验

2026-10-140
OAAI
Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer

不利的中危局限性前列腺癌中不一致的分子生物标志物

2026-08-250
OAAI
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial

持续性雄激素剥夺疗法联合或未联合转移灶定向治疗寡转移性前列腺癌:多中心II期随机EXTEND试验

2025-07-310
PRE
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis

随机化Ⅱ期临床试验:针对出现淋巴结转移的前列腺癌患者,比较术前雄激素剥夺疗法联合或不联合Axitinib的治疗效果

2025-07-120
PRE
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance
2024-11-090
OAAI
Prostate cancer-induced endothelial- cell- to- osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization

前列腺癌诱导的内皮细胞向成骨细胞转化通过Wnt通路诱导的M2巨噬细胞极化驱动骨肿瘤微环境中的免疫抑制

2024-08-052
OAAI
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates

阿帕鲁胺治疗中危前列腺癌的II期试验及其分子相关性

2024-06-041
PRE
KDM4A promotes NEPC progression through regulation of MYC expression
2023-04-040
PRE
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
2023-03-228
OAAI
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones
2022-09-134
PRE
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
2021-06-2233
OAAI
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

ipilimumab治疗前列腺癌患者后的新抗原反应,免疫相关性和有利结果

2020-04-01116
PREAI